IRONWOOD PHARMACEUTICALS, INC. Interest Expense Nonoperating
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Interest Expense Nonoperating of $7.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $7.20M, a 13.80% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $9.14M, a 13.27% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $7.89M, a 11.53% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $8.43M, a 10.46% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $32.75M, a 0.87% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $33.03M, a 52.73% increase from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $21.63M, a 184.67% increase from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $7.60M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.20M 10-Q · filed 2026-08-06 | $16.34M 10-Q · filed 2026-08-06 | $24.23M derived: sum of 3 quarters · filed 2026-08-06 | $32.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.14M 10-Q · filed 2026-05-07 | $17.03M derived: sum of 2 quarters · filed 2026-05-07 | $25.46M derived: sum of 3 quarters · filed 2026-05-07 | $33.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.32M derived: sum of 2 quarters · filed 2026-02-26 | $24.68M derived: sum of 3 quarters · filed 2026-08-06 | $32.75M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.43M 10-Q · filed 2025-11-10 | $16.79M derived: sum of 2 quarters · filed 2026-08-06 | $24.86M 10-Q · filed 2025-11-10 | $33.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.36M 10-Q · filed 2026-08-06 | $16.43M 10-Q · filed 2026-08-06 | $25.34M derived: sum of 3 quarters · filed 2026-08-06 | $34.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $8.07M 10-Q · filed 2026-05-07 | $16.98M derived: sum of 2 quarters · filed 2026-05-07 | $26.40M derived: sum of 3 quarters · filed 2026-05-07 | $33.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.33M derived: sum of 2 quarters · filed 2026-02-26 | $25.80M derived: sum of 3 quarters · filed 2026-02-26 | $33.03M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.42M 10-Q · filed 2025-11-10 | $16.89M derived: sum of 2 quarters · filed 2025-11-10 | $24.12M 10-Q · filed 2025-11-10 | $32.54M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $7.47M 10-Q · filed 2025-08-11 | $14.70M 10-Q · filed 2025-08-11 | $23.12M derived: sum of 3 quarters · filed 2025-08-11 | $32.96M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $7.23M 10-Q · filed 2025-05-12 | $15.65M derived: sum of 2 quarters · filed 2025-05-12 | $25.49M derived: sum of 3 quarters · filed 2025-05-12 | $27.33M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $18.26M derived: sum of 2 quarters · filed 2025-03-31 | $20.10M derived: sum of 3 quarters · filed 2025-03-31 | $21.63M 10-K · filed 2025-03-31 |
| 2023-09-30 | $9.84M 10-Q · filed 2024-11-07 | $11.68M derived: sum of 2 quarters · filed 2024-11-07 | $13.21M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.84M 10-Q · filed 2024-08-08 | $3.37M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $7.60M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |